GSK-Spero’s oral antibiotic Utebzi (tebipenem pivoxil hydrobromide) won FDA approval for complicated urinary tract infections, including pyelonephritis. The approval comes about four years after the agency issued a complete response letter, with Phase III data supporting noninferiority to IV imipenem-cilastatin, Spero and GSK said.